A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.

@article{Katsumata2000API,
  title={A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.},
  author={Noriyuki Katsumata and Ryuichiro Tsunematsu and K Tanaka and Yasushi Terashima and Shin Ogita and Hiroshi Hoshiai and Ichiro Kohno and Kouji Hirabayashi and Masashi Yakushiji and Kiichiro Noda and Tetsuo Taguchi},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 12},
  pages={
          1531-6
        }
}
BACKGROUND This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer. PATIENTS AND METHODS Docetaxel was administered at a dose of 70 mg/m2 intravenously to patients with platinum pretreated advanced ovarian cancer. Treatment was repeated every three weeks. No routine corticosteroid premedication was given. RESULTS Ninety patients with advanced ovarian cancer were entered and sixty were assessable for response. The… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Docetaxel: an alternative taxane in ovarian cancer

  • British Journal of Cancer
  • 2003
VIEW 7 EXCERPTS
CITES BACKGROUND

Docetaxel: promising and novel combinations in ovarian cancer

  • British Journal of Cancer
  • 2003
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].

  • Gan to kagaku ryoho. Cancer & chemotherapy
  • 1994
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
VIEW 1 EXCERPT

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
VIEW 1 EXCERPT

Docetaxel (Taxotere): A new active agent by WHO and CA125 response criteria, in platinumpretreated advanced epithelial ovarian cancer

MJ Piccart, GJ Rustin, M. Gore
  • Ovarian Cancer, Volume
  • 1996
VIEW 1 EXCERPT

Phase II study of docetaxel in patients with epitelial ovarian carcinoma refractory to platinum

J Kavanagh, AP Kudelka, C Gonzalez de Leon
  • Clin Cancer Res
  • 1996
VIEW 2 EXCERPTS